Evidence map›Paper›PMID 39363045›Full record

ArticleNPJ precision oncology2024

Proteomic basis for pancreatic acinar cell carcinoma and pancreatoblastoma as similar yet distinct entities.

Atsushi Tanaka, Makiko Ogawa, Yihua Zhou, Ronald C Hendrickson, Matthew M Miele, Zhuoning Li, David S Klimstra, Julia Y Wang, Michael H A Roehrl

Abstract read
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Atsushi TanakaDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Makiko OgawaDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Yihua ZhouDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ronald C HendricksonSloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matthew M MieleSloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7495-2133
Zhuoning LiSloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David S KlimstraDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julia Y WangCurandis Biomedical, Chestnut Hill, MA, USA. julia@curandis.com.ORCID http://orcid.org/0000-0002-9458-5825
Michael H A RoehrlDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. michael_roehrl@bidmc.harvard.edu.ORCID http://orcid.org/0000-0003-4892-1098

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology PatientsU01CA263986 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Wenyi Wei · 2022 to 2026
$1.3M
Proteomic Characterization of Genomically Complex SarcomasR21CA251992 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROEHRL, MICHAEL H. A. · 2020 to 2020
$487k
Proteomic Characterization of Pancreatic Neuroendocrine Tumors and Metastatic ProgressionR21CA263262 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROEHRL, MICHAEL H. A. · 2021 to 2022
$450k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA251992NCI NIH HHS R21 CA263262NCI NIH HHS U01 CA263986Neuroendocrine Tumor Research Foundation (NET Research Foundation) N/A
6 · The paper itself

Abstract

Acinar cell carcinoma (ACC) and pancreatoblastoma (PBL) are rare pancreatic malignancies with acinar differentiation. Proteogenomic profiling of ACC and PBL revealed distinct protein expression patterns compared to pancreatic ductal adenocarcinoma (PDAC) and benign pancreas. ACC and PBL exhibited similarities, with enrichment in proteins related to RNA processing, chromosome organization, and the mitoribosome, while PDACs overexpressed proteins associated with actin-based processes, extracellular matrix, and immune-active stroma. Pathway activity differences in metabolic adaptation, epithelial-to-mesenchymal transition, and DNA repair were characterized between these diseases. PBL showed upregulation of Wnt-CTNNB1 and IGF2 pathways. Seventeen ACC-specific proteins suggested connections to metabolic diseases with mitochondrial dysfunction, while 34 PBL-specific proteins marked this pediatric cancer with an embryonic stem cell phenotype and alterations in chromosomal proteins and the cell cycle. This study provides novel insights into the proteomic landscapes of ACC and PBL, offering potential targets for diagnostic and therapeutic development.

Identifiers

PMID39363045
PMCPMC11449907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.